Tvardi Therapeutics Inc. Common Stock (TVRD)
Stock · NASDAQ · Health Care
$1.01as of 10/16/2026
Price chart
Active signals
TVRD Signal Track Record
How signals performed across all stocks →What TVRD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 25 | -4.3% | 40% | September 17, 2026 |
| Bollinger Band Breakdown | 23 | -8.0% | 43% | September 17, 2026 |
| Bollinger Band Breakout | 24 | -6.5% | 42% | July 8, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +9.2% | 56% | March 4, 2025 |
| Any 20-session window (baseline) | -5.2% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TVRD
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 12
- Website
- tvarditherapeutics.com
Fundamentals
- 1-day range
- $1$1.06
- Market cap
- $23.02M
- P/E (trailing)
- —
- P/E (forward)
- -0.45
- EPS (trailing)
- $-2.78
- Dividend yield
- —
- Beta
- 0.30
- Avg. volume
- 277.1K
How Tvardi Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 11, 2025 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Tvardi Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
- IGCIGC Pharma Inc. Common Stock$0.25▲ 0.00%Market cap $23.94MP/E —$0.235$0.4508
- CALCCalciMedica Inc. Common Stock$1.04▼ 3.70%Market cap $21.88MP/E —$1.27$36
- TXMDTherapeuticsMD Inc. Common Stock$1.9▼ 1.55%Market cap $24.19MP/E 135.01$1.03$2.95
- ALLRAllarity Therapeutics Inc. Common Stock$0.895▲ 7.44%Market cap $21.65MP/E —$0.769$1.84
- LGVNLongeveron Inc. Class A Common Stock$1.39▼ 7.33%Market cap $24.44MP/E —$1.69$12.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
| IGC IGC Pharma Inc. Common Stock | $23.94M | — | $0.25 | ▲ 0.00% | $0.235$0.4508 |
| CALC CalciMedica Inc. Common Stock | $21.88M | — | $1.04 | ▼ 3.70% | $1.27$36 |
| TXMD TherapeuticsMD Inc. Common Stock | $24.19M | 135.01 | $1.9 | ▼ 1.55% | $1.03$2.95 |
| ALLR Allarity Therapeutics Inc. Common Stock | $21.65M | — | $0.895 | ▲ 7.44% | $0.769$1.84 |
| LGVN Longeveron Inc. Class A Common Stock | $24.44M | — | $1.39 | ▼ 7.33% | $1.69$12.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga · 10/1/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 9/30/2026
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · 9/24/2026
- Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciencesbenzinga · 9/24/2026
- New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)Yahoo · 9/24/2026
- Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular SciencesBenzinga · 9/24/2026
Insider Activity
Insider Actions →- Shiff Susan Ph.D. · June 9, 2026 · Grant6.0K
- HALL WALLACE L JR · June 9, 2026 · Grant6.0K
- Smith Cynthia · June 9, 2026 · Grant6.0K
- Shah Sujal · June 9, 2026 · Grant6.0K
- Michael S. Wyzga · June 9, 2026 · Grant6.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.62M
- Total value held
- $8.32M
- Institutional holders
- 63
- Unknown704.1K
- Unknown388.1K
- Unknown344.7K
- Unknown223.7K
- Unknown182.3K
- Unknown101.0K
- Unknown97.2K
- Unknown92.1K
- Unknown72.9K
- Unknown63.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Tvardi releases preclinical data on STAT3 inhibitor for UC
Tvardi Therapeutics reported new preclinical results that show its STAT3 inhibitor may be effective in treating ulcerative colitis. The data were published in the International Journal of Molecular Sciences. The announcement appeared in recent market round‑ups of health‑care stocks moving in pre‑market and after‑hours sessions.
Tvardi releases preclinical data on STAT3 inhibitor for UC. Tvardi Therapeutics reported new preclinical results that show its STAT3 inhibitor may be effective in treating ulcerative colitis. The data were published in the International Journal of Molecular Sciences. The announcement appeared in recent market round‑ups of health‑care stocks moving in pre‑market and after‑hours sessions.